Investigators: Alexia Foti, Anthony Kicic, Erika Sutanto, Fergal O'Gara, Jose A Caparros-Martin, Luke Garratt, Patricia Agudelo Romero, Stephen Stick, Yuliya Karpievitch
Project description
Cystic fibrosis related progressive lung disease characterised by inflammation and infection commences soon after birth. Candidate triggers are emerging from work undertaken by the chief investigators. The grant will facilitate a comprehensive assessment of these candidates and the host responses as biomarkers of disease progression and targets for intervention in order to prevent lung disease.
The Synergy program will provide a detailed and definitive understanding of early CF lung pathobiology including:
- Identification of early biomarkers of disease progression and irreversible lung damage so that early disease trajectory can be accurately characterised
- Development of interventions that can be used as first line therapy or adjuncts to CFTR modulator therapy with the goal of preventing irreversible lung disease.
Project outputs
The outcomes will provide the global CF community with the information required to assess the risk:benefit of early CFTR modulator therapy and the development of a personalised approach to early intervention with using alternative strategies.
Collaborators
- Sarath Ranganathan (Murdoch Children's Research Institute)
- Richard C Boucher (University of North Carolina)
- Elaine Holmes (Australian National Phenome Centre)
- Rabindra Tirouvanziam (Emory University)